EN
抗体药类似物
Research Grade Telitacicept
All
  • CatalogTD-HV212046
  • Clonality
  • Application Research Grade Biosimilar
  • SynonymsRC18,CAS:2136630-26-5
  • 规格
    1mg
  • 价格
    ¥询价
定制服务咨询

Research Grade Telitacicept


Catalog No. TD-HV212046
Species reactivity Human
Applications Research Grade Biosimilar
Isotype Fusion - [TNFRSF13B (tumor necrosis factor receptor (TNFR) superfamily member 13B, TACI, transmembrane activator and CAML Interactor)]2 - IGHG1 Fc (Fragment constant)
Expression system Mammalian Cells
Target BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor
Endotoxin level Please contact the lab for this information.
Purity >95% purity as determined by SDS-PAGE.
Purification Protein A/G, purified from cell culture supernatant.
Accession Q9Y275
Form Liquid
Storage buffer 0.01M PBS,pH7.4.
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C for short-term storage (1-2 weeks). Store at -20°C for up to 12 months. For long-term storage, store at -80°C.
Alternate Names RC18,CAS:2136630-26-5
Background Telitacicept (RC18) is a fully human TACI-Fc fusion protein. Telitacicept is a dual B lymphocyte stimulator (BLyS)/APRIL (a proliferation-inducing ligand) inhibitor that effectively blocks proliferation of B lymphocytes. Telitacicept can be used in research of B-cell autoimmune disease.
Note For research use only. Not for use in clinical or therapeutic applications.